Market's view on Provexis
Published on April 2024
- ByHealth Co., Ltd is implementing a “going global” strategy to explore the core market in Southeast Asia and establish a network-wide digital media center and digital platform for members. This is part of its omni-channel single focus strategy for multiple brands and categories.
- Stock watchers express concerns regarding the need for funds to stock up on raw ingredients prior to a product launch, with shelf life not being an issue and DSM seeing value in taking paper from ByHealth.
- Uncertainties related to funding and shelf life are acknowledged but are believed to be partially resolved, with the market reacting positively to the placement.
- The registration process for ByHealth’s products with CFE/SAMR is ongoing, involving multiple stages including data evaluation, testing proposals, and dossier preparation, but the status of the application is unclear.
- Stock watchers discuss the opacity in financial reporting and the challenges in understanding the underlying financial health of the company, with some financial maneuvers believed to be aimed at flattering financial contributions.
- There is a debate about the level of transparency regarding royalty reporting and payments, with some stock watchers feeling that details are unnecessarily withheld.
- Sales figures show significant growth, but issues such as a dramatic increase in the cost of sales are causing concerns about the company’s financial management and the impact on gross profit.
- Concerns are raised about ByHealth’s ability to maintain profit margins when major deals are finalized, with expectations of discounts that could affect profitability.
- There is skepticism about the interest from global brand owners in the company’s products, suggesting a persistent lack of genuine interest despite many years of effort.
- Discussions about the company’s management reveal concerns over the executive’s compensation in relation to company performance, with debates about the appropriateness of the salary given the financial state of the company.